Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355338 | 0.85 | AVPR1B (0.38) | NPC1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL14577844 | 0.81 | AVPR1B (0.36) | NPC1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL5219908 | 0.67 | FPR2 (0.38) | KMT2AROCK2ROCK1LMNARAB9A | |
| SCHEMBL6078968 | 0.66 | MAPT (0.43) | NPC1MEN1KMT2ATDP1LMNA | |
| SCHEMBL6078926 | 0.62 | ALDH1A1 (0.50) | NPC1MEN1KMT2ATDP1RAB9A | |
| SCHEMBL27842540 | 0.61 | TP53 (0.36) | MEN1KMT2ALMNA | |
| SCHEMBL6079022 | 0.61 | PDE5A (0.42) | NPC1MEN1KMT2ATDP1LMNA | |
| SCHEMBL10085254 | 0.60 | LMNA (0.57) | NPC1MEN1KMT2ATDP1LMNA | |
| SCHEMBL353320 | 0.60 | ROCK1 (0.61) | ROCK2ROCK1 | |
| SCHEMBL10084856 | 0.60 | KMT2A (0.49) | NPC1MEN1KMT2AROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ZC3HAV1, CD4, ACIN1 | NPC1 1868/4885MEN1 4767/4885KMT2A 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.